^
Association details:
| Biomarker: | CDKN2A deletion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genomic Determinants of Response to Blinatumomab in Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia in Adults
Published date:
11/01/2018
Excerpt:
We studied 29 patients...with R/R B-ALL who were treated with up to 5 cycles of blinatumomab...Alterations affecting the cell cycle (CDKN2A/B, TP53, RB1) were observed at a high frequency in pre-blinatumomab samples (15 of 22, 68%), with CDKN2A/B deletions enriched in responders compared to non-responders (11 of 14, 79% vs. 2 of 8, 25%; P=0.026).
DOI:
10.1182/blood-2018-99-113604
